Abbott Laboratories (ABT) Short term Debt (2009 - 2026)

Abbott Laboratories has disclosed Short term Debt across 18 years of filings, most recently posting $4.4 billion for Q1 2026.

• Short term Debt for Q1 2026 came in at $4.4 billion, up 771.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 billion (up 771.34% YoY), and the FY2025 annual result was $3.0 billion, up 102.2% from the prior year.
• Short term Debt came in at $4.4 billion for Q1 2026 at Abbott Laboratories, up from $3.0 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $4.4 billion in Q1 2026 to a low of $4.0 million in Q1 2022.
• The 5-year median for Short term Debt is $1.5 billion (2024), against an average of $1.6 billion.
• Across the five-year window, Short term Debt slumped 97.99% in 2022 and jumped 57025.0% in 2023, its largest moves.
• Abbott Laboratories' Short term Debt stood at $2.3 billion in 2022, then tumbled by 52.02% to $1.1 billion in 2023, then soared by 38.89% to $1.5 billion in 2024, then surged by 102.2% to $3.0 billion in 2025, then jumped by 45.37% to $4.4 billion in 2026.
• The last three Short term Debt figures came in at $4.4 billion (Q1 2026), $3.0 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.